Lupus & antiphospholipid syndrome
Hydroxychloroquine Dose and Hospitalizations for Active Lupus
Authors' conclusion
The use of lower doses of HCQ was associated with an increased risk of hospitalizations for active SLE.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE) using hydroxychloroquine (HCQ) with ≥1 hospitalization for active SLE, academic health system, January 2011–December 2021from 2,974 HCQ users
- Participants
- 122 patients
- Comparison
- Lower vs higher HCQ dose
- Outcome
- Hospitalization for active SLE
- Follow-up
- Six-month case or control period
Methodological detailsconditional logistic regression, single academic health system
- Conditional logistic regression
- Single academic health system
Main finding
As reported in the abstract
Hospitalizations for active SLE
Adjusted odds ratio (95% CI)
≤5 mg/kg/dayvs >5 mg/kg/day
4.20(1.45–12.19)
<400 mg/dayvs 400 mg/day
3.39(1.31–8.81)
Original publication
Hydroxychloroquine Dose and Hospitalizations for Active Lupus. Arthritis Rheumatol. Published 21 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →